University of Georgia
Ivelin Georgiev lab
A significant challenge that has hindered the development of an effective HIV-1 vaccine is the limited ability to study antibody responses to vaccination. In particular, current approaches for characterizing antibody responses to vaccination are limited in their ability to generate high-resolution antigen specificity information linked to antibody sequence, thus providing an incomplete understanding of the types and specificities of vaccine-elicited antibody repertoires. To address this issue, we recently developed LIBRA-seq, a technology that enables high-throughput mapping of antibody sequence to antigen specificity for a theoretically unlimited number of antigens, from a single next-generation sequencing experiment. Parker’s project will focus on applying the LIBRA-seq technology to the characterization of antibody responses to vaccination with multivalent immunogens. These efforts will lead to new insights into how the human immune system responds to multivalent vaccines that incorporate a cocktail of multiple different HIV-1 strains.